Publicacions en què col·labora amb ATANASIO PANDIELLA ALONSO (10)

2015

  1. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone

    Leukemia, Vol. 29, Núm. 3, pp. 705-714

2012

  1. CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype

    Haematologica, Vol. 97, Núm. 7, pp. 1110-1114

  2. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

    Leukemia, Vol. 26, Núm. 8, pp. 1862-1869

2011

  1. Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response

    Haematologica, Vol. 96, Núm. 5, pp. 687-695

2009

  1. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors

    Leukemia, Vol. 23, Núm. 8, pp. 1515-1527

2006

  1. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance

    Cancer Research, Vol. 66, Núm. 11, pp. 5781-5789

2005

  1. Bortezomib is an efficient agent in plasma cell leukemias

    International Journal of Cancer, Vol. 114, Núm. 4, pp. 665-667

  2. Genetic abnormalities and patterns of antigenic expression in multiple myeloma

    Clinical Cancer Research, Vol. 11, Núm. 10, pp. 3661-3667

  3. Multifunctional role of Erk5 in multiple myeloma

    Blood, Vol. 105, Núm. 11, pp. 4492-4499

2003

  1. Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents

    British Journal of Haematology, Vol. 123, Núm. 5, pp. 858-868